{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T02:12:36Z","timestamp":1778551956764,"version":"3.51.4"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"The Medical Science Research Project of Hebei Province, China","award":["No. 20250800"],"award-info":[{"award-number":["No. 20250800"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s00228-026-04060-4","type":"journal-article","created":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T06:59:53Z","timestamp":1777445993000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Age-stratified nomogram development and validation for predicting voriconazole trough concentrations above safety threshold in pediatric patients with hematologic malignancy"],"prefix":"10.1007","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-2501-2538","authenticated-orcid":false,"given":"Na","family":"An","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2851-6810","authenticated-orcid":false,"given":"Yu","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-7415-071X","authenticated-orcid":false,"given":"Chenhong","family":"Jia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-2695-0257","authenticated-orcid":false,"given":"Weijing","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2318-3756","authenticated-orcid":false,"given":"Yile","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,29]]},"reference":[{"key":"4060_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/etm.2025.13016","volume":"31","author":"M He","year":"2025","unstructured":"He M, Chen F, Xian X, Guo Z (2025) Diagnosis and treatment of invasive fungal disease in children with hematological malignancies after chemotherapy: challenges and strategies (review). Exp Ther Med 31:1\u201317. https:\/\/doi.org\/10.3892\/etm.2025.13016","journal-title":"Exp Ther Med"},{"key":"4060_CR2","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1097\/FTD.0000000000000561","volume":"40","author":"K Chen","year":"2018","unstructured":"Chen K, Zhang X, Ke X et al (2018) Individualized medication of voriconazole: a practice guideline of the Division of Therapeutic Drug Monitoring, Chinese Pharmacological Society. Ther Drug Monit 40:663\u2013674. https:\/\/doi.org\/10.1097\/FTD.0000000000000561","journal-title":"Ther Drug Monit"},{"key":"4060_CR3","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.ijantimicag.2006.01.003","volume":"27","author":"D Leveque","year":"2006","unstructured":"Leveque D, Nivoix Y, Jehl F, Herbrecht R (2006) Clinical pharmacokinetics of voriconazole. Int J Antimicrob Agents 27:274\u2013284. https:\/\/doi.org\/10.1016\/j.ijantimicag.2006.01.003","journal-title":"Int J Antimicrob Agents"},{"key":"4060_CR4","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00207-21","volume":"65","author":"X Tian","year":"2021","unstructured":"Tian X, Zhang C, Qin Z et al (2021) Impact of CYP2C19 phenotype and drug-drug interactions on voriconazole concentration in pediatric patients. Antimicrob Agents Chemother 65:e00207-21. https:\/\/doi.org\/10.1128\/AAC.00207-21","journal-title":"Antimicrob Agents Chemother"},{"key":"4060_CR5","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1002\/jcph.1422","volume":"59","author":"M Mafuru","year":"2019","unstructured":"Mafuru M, Wu S, He S et al (2019) The influence of proinflammatory cytokines on voriconazole trough concentration in patients with different forms of hematologic disorders. J Clin Pharmacol 59:1340\u20131350. https:\/\/doi.org\/10.1002\/jcph.1422","journal-title":"J Clin Pharmacol"},{"key":"4060_CR6","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1177\/1060028020948174","volume":"55","author":"J Lee","year":"2021","unstructured":"Lee J, Ng P, Hamandi B et al (2021) Effect of therapeutic drug monitoring and Cytochrome P450 2C19 genotyping on clinical outcomes of voriconazole: a systematic review. Ann Pharmacother 55:509\u2013529. https:\/\/doi.org\/10.1177\/1060028020948174","journal-title":"Ann Pharmacother"},{"issue":"2","key":"4060_CR7","doi-asserted-by":"publisher","first-page":"562","DOI":"10.19746\/j.cnki.issn.1009-2137.2023.02.036","volume":"31","author":"HG Huang","year":"2023","unstructured":"Huang HG, Wang HL, Lin YK et al (2023) Factors Influencing and Adverse Reactions of Voriconazole Clearance in Patients with Hematological Diseases. Zhongguo Shi Yan Xue Ye Xue Za Zhi 31(2):562\u2013567. https:\/\/doi.org\/10.19746\/j.cnki.issn.1009-2137.2023.02.036","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"issue":"6","key":"4060_CR8","first-page":"653","volume":"29","author":"JX Zhou","year":"2024","unstructured":"Zhou JX, Li YF, Lyu FJ et al (2024) Construction of a risk prediction model for high voriconazole blood concentration. Chin J Clin Pharmacol Ther 29(6):653\u2013660","journal-title":"Chin J Clin Pharmacol Ther"},{"issue":"23","key":"4060_CR9","doi-asserted-by":"publisher","first-page":"3399","DOI":"10.13748\/j.cnki.issn1007-7693.20233325","volume":"41","author":"LL Dong","year":"2024","unstructured":"Dong LL, Hu N, Jiang Y et al (2024) Establishment and evaluation of a risk prediction model for voriconazole concentration exceeding the upper limit of reference range. Chin J Mod Appl Pharm 41(23):3399\u20133405. https:\/\/doi.org\/10.13748\/j.cnki.issn1007-7693.20233325","journal-title":"Chin J Mod Appl Pharm"},{"issue":"3","key":"4060_CR10","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1080\/1120009X.2024.2376453","volume":"37","author":"M Xie","year":"2024","unstructured":"Xie M, Jiang M, Xu J et al (2024) Development and validation of a clinical risk score nomogram for predicting voriconazole trough concentration above 5 mg\/L: a retrospective cohort study. J Chemother 37(3):229\u2013237. https:\/\/doi.org\/10.1080\/1120009X.2024.2376453","journal-title":"J Chemother"},{"key":"4060_CR11","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1097\/FTD.0000000000000804","volume":"42","author":"S Kang","year":"2020","unstructured":"Kang S, Yee J, Kim JY et al (2020) Factors associated with voriconazole concentration in pediatric patients. Ther Drug Monit 42:866\u2013871. https:\/\/doi.org\/10.1097\/FTD.0000000000000804","journal-title":"Ther Drug Monit"},{"issue":"11","key":"4060_CR12","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01126-24","volume":"68","author":"L Hu","year":"2024","unstructured":"Hu L, Su Y, Tang X et al (2024) Therapeutic drug monitoring and safety of voriconazole in patients with liver dysfunction. Antimicrob Agents Chemother 68(11):e0112624. https:\/\/doi.org\/10.1128\/aac.01126-24","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"4060_CR13","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00955-18","volume":"62","author":"L Hu","year":"2018","unstructured":"Hu L, Dai TT, Zou L et al (2018) Therapeutic drug monitoring of voriconazole in children from a tertiary care center in China. Antimicrob Agents Chemother 62(12):e00955-18. https:\/\/doi.org\/10.1128\/aac.00955-18","journal-title":"Antimicrob Agents Chemother"},{"key":"4060_CR14","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00623-21","volume":"65","author":"T Takahashi","year":"2021","unstructured":"Takahashi T, Mohamud MA, Smith AR et al (2021) CYP2C19 phenotype and body weight-guided voriconazole initial dose in infants and children after hematopoietic cell transplantation. Antimicrob Agents Chemother 65:e00623-21. https:\/\/doi.org\/10.1128\/AAC.00623-21","journal-title":"Antimicrob Agents Chemother"},{"key":"4060_CR15","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1128\/AAC.04093-14","volume":"59","author":"M Mori","year":"2015","unstructured":"Mori M, Kobayashi R, Kato K et al (2015) Pharmacokinetics and safety of voriconazole intravenous-to-oral switch regimens in immunocompromised Japanese pediatric patients. Antimicrob Agents Chemother 59:1004\u20131013. https:\/\/doi.org\/10.1128\/AAC.04093-14","journal-title":"Antimicrob Agents Chemother"},{"key":"4060_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s13052-024-01684-z","volume":"50","author":"L Hu","year":"2024","unstructured":"Hu L, Huang J, Li Y, He G (2024) Clinical application of Voriconazole in pediatric patients: a systematic review. Ital J Pediatr 50:113. https:\/\/doi.org\/10.1186\/s13052-024-01684-z","journal-title":"Ital J Pediatr"},{"key":"4060_CR17","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1080\/1120009X.2020.1765604","volume":"33","author":"X Luo","year":"2021","unstructured":"Luo X, Li T, Hu L et al (2021) Differential effects of C-Reactive Protein levels on Voriconazole metabolism at three age groups in allogeneic Hematopoietic Cell Transplant recipients. J Chemother 33:95\u2013105. https:\/\/doi.org\/10.1080\/1120009X.2020.1765604","journal-title":"J Chemother"},{"key":"4060_CR18","doi-asserted-by":"publisher","first-page":"5166","DOI":"10.1111\/bcp.15495","volume":"88","author":"X Li","year":"2022","unstructured":"Li X, Lai F, Jiang Z et al (2022) Effects of inflammation on Voriconazole levels: a systematic review. Br J Clin Pharmacol 88:5166\u20135182. https:\/\/doi.org\/10.1111\/bcp.15495","journal-title":"Br J Clin Pharmacol"},{"key":"4060_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2023.106750","volume":"61","author":"DA Van Den Born","year":"2023","unstructured":"Van Den Born DA, M\u00e4rtson AG, Veringa A et al (2023) Voriconazole exposure is influenced by inflammation: a population pharmacokinetic model. Int J Antimicrob Agents 61:106750. https:\/\/doi.org\/10.1016\/j.ijantimicag.2023.106750","journal-title":"Int J Antimicrob Agents"},{"key":"4060_CR20","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1002\/jcph.2024","volume":"62","author":"T Takahashi","year":"2022","unstructured":"Takahashi T, Jaber MM, Smith AR et al (2022) Predictive value of C-Reactive Protein and Albumin for temporal within\u2010individual pharmacokinetic variability of Voriconazole in pediatric patients undergoing Hematopoietic Cell Transplantation. J Clin Pharmacol 62:855\u2013862. https:\/\/doi.org\/10.1002\/jcph.2024","journal-title":"J Clin Pharmacol"},{"key":"4060_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2022.846411","volume":"10","author":"J Chen","year":"2022","unstructured":"Chen J, Wu Y, He Y et al (2022) Combined effect of CYP2C19 genetic polymorphisms and C-Reactive Protein on Voriconazole exposure and dosing in immunocompromised children. Front Pediatr 10:846411. https:\/\/doi.org\/10.3389\/fped.2022.846411","journal-title":"Front Pediatr"},{"key":"4060_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2020.107627","volume":"215","author":"F Stanke-Labesque","year":"2020","unstructured":"Stanke-Labesque F, Gautier-Veyret E, Chhun S, Guilhaumou R (2020) Inflammation is a major regulator of drug metabolizing enzymes and transporters: consequences for the personalization of drug treatment. Pharmacol Ther 215:107627. https:\/\/doi.org\/10.1016\/j.pharmthera.2020.107627","journal-title":"Pharmacol Ther"},{"key":"4060_CR23","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1097\/FTD.0000000000000799","volume":"42","author":"P Chantharit","year":"2020","unstructured":"Chantharit P, Tantasawat M, Kasai H, Tanigawara Y (2020) Population pharmacokinetics of Voriconazole in patients with Invasive Aspergillosis: Serum Albumin level as a novel marker for clearance and dosage optimization. Ther Drug Monit 42:872\u2013879. https:\/\/doi.org\/10.1097\/FTD.0000000000000799","journal-title":"Ther Drug Monit"},{"key":"4060_CR24","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1111\/myc.13570","volume":"66","author":"C Boglione-Kerrien","year":"2023","unstructured":"Boglione-Kerrien C, Morcet J, Scailteux L et al (2023) Contribution of voriconazole N\u2010oxide plasma concentration measurements to voriconazole therapeutic drug monitoring in patients with invasive fungal infection. Mycoses 66:396\u2013404. https:\/\/doi.org\/10.1111\/myc.13570","journal-title":"Mycoses"},{"key":"4060_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics10121542","volume":"10","author":"YC Zhao","year":"2021","unstructured":"Zhao YC, Zou Y, Hou JJ et al (2021) Factors affecting voriconazole trough concentration and optimal maintenance voriconazole dose in Chinese children. Antibiotics Basel 10:1542. https:\/\/doi.org\/10.3390\/antibiotics10121542","journal-title":"Antibiotics Basel"},{"key":"4060_CR26","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1093\/jac\/dku529","volume":"70","author":"JA Trubiano","year":"2015","unstructured":"Trubiano JA, Crowe A, Worth LJ, Thursky KA, Slavin MA (2015) Putting CYP2C19 genotyping to the test: utility of pharmacogenomic evaluation in a voriconazole-treated haematology cohort. J Antimicrob Chemother 70:1161\u20131165. https:\/\/doi.org\/10.1093\/jac\/dku529","journal-title":"J Antimicrob Chemother"},{"key":"4060_CR27","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1177\/039139889601900305","volume":"19","author":"AH Sklar","year":"1996","unstructured":"Sklar AH, Riesenberg LA, Ur Rehman A, Smith S, Rivera-Padilla H (1996) Prerenal azotemia: differentiation of hyperureagenesis from renal hypoperfusion using urinary urea nitrogen data. Int J Artif Organs 19:164\u2013169. https:\/\/doi.org\/10.1177\/039139889601900305","journal-title":"Int J Artif Organs"},{"key":"4060_CR28","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.accreview.2004.06.003","volume":"116","author":"D Aronson","year":"2004","unstructured":"Aronson D, Mittleman MA, Burger AJ (2004) Elevated blood urea nitrogen level as a predictor of mortality in patients admitted for decompensated heart failure. Am J Med 116:466\u2013473. https:\/\/doi.org\/10.1016\/j.accreview.2004.06.003","journal-title":"Am J Med"},{"issue":"1","key":"4060_CR29","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1023\/a:1021346401701","volume":"34","author":"DA Feinfeld","year":"2002","unstructured":"Feinfeld DA, Bargouthi H, Niaz Q, Carvounis CP (2002) Massive and disproportionate elevation of blood urea nitrogen in acute azotemia. Int Urol Nephrol 34(1):143\u2013145. https:\/\/doi.org\/10.1023\/a:1021346401701","journal-title":"Int Urol Nephrol"},{"issue":"7","key":"4060_CR30","doi-asserted-by":"publisher","first-page":"690.e1","DOI":"10.1016\/j.jtct.2024.04.006","volume":"30","author":"G Salinas Cisneros","year":"2024","unstructured":"Salinas Cisneros G, Dvorak CC, Long-Boyle J et al (2024) Diagnosing and grading of sinusoidal obstructive syndrome after hematopoietic stem cell transplant of children, adolescent and young adults treated in a pediatric institution with pediatric protocols. Transplant Cell Ther 30(7):690.e1\u2013690.e16. https:\/\/doi.org\/10.1016\/j.jtct.2024.04.006","journal-title":"Transplant Cell Ther"},{"issue":"4","key":"4060_CR31","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.cld.2010.08.002","volume":"14","author":"JM Crawford","year":"2010","unstructured":"Crawford JM (2010) Vascular disorders of the liver. Clin Liver Dis 14(4):635\u2013650. https:\/\/doi.org\/10.1016\/j.cld.2010.08.002","journal-title":"Clin Liver Dis"},{"issue":"9","key":"4060_CR32","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.15449","volume":"38","author":"K Cui","year":"2024","unstructured":"Cui K, Chen J, Zhang S et al (2024) Risk factors for Sinusoidal Obstruction Syndrome after Hematopoietic Stem Cell Transplantation in children and young adults: A systematic review and meta-analysis. Clin Transplant 38(9):e15449. https:\/\/doi.org\/10.1111\/ctr.15449","journal-title":"Clin Transplant"},{"key":"4060_CR33","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1111\/bcp.13401","volume":"84","author":"S Allegra","year":"2018","unstructured":"Allegra S, Fatiguso G, De Francia S et al (2018) Therapeutic drug monitoring of voriconazole for treatment and prophylaxis of invasive fungal infection in children. Br J Clin Pharmacol 84:197\u2013203. https:\/\/doi.org\/10.1111\/bcp.13401","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"4060_CR34","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1093\/cid\/cix443","volume":"65","author":"M Mahmoudi","year":"2017","unstructured":"Mahmoudi M, Brenner T, Hatiboglu G et al (2017) Substantial impairment of voriconazole clearance by high-dose meropenem in a patient with renal failure. Clin Infect Dis 65(6):1033\u20131036. https:\/\/doi.org\/10.1093\/cid\/cix443","journal-title":"Clin Infect Dis"},{"key":"4060_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1292163","volume":"15","author":"BN Huo","year":"2024","unstructured":"Huo BN, Shu L, Xiao JW et al (2024) Clinical drug interactions between voriconazole and 38 other drugs: a retrospective analysis of adverse events. Front Pharmacol 15:1292163. https:\/\/doi.org\/10.3389\/fphar.2024.1292163","journal-title":"Front Pharmacol"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-026-04060-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-026-04060-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-026-04060-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T01:46:35Z","timestamp":1778550395000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-026-04060-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,29]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["4060"],"URL":"https:\/\/doi.org\/10.1007\/s00228-026-04060-4","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,29]]},"assertion":[{"value":"21 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"135"}}